RxDoctor Payments Data

Erin Cacciola, PA

Medical · Nashua, NHNPI 1932442373

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $302 of the $348 with a category attached, or 86.8%. 8 manufacturers reported payments, led by AstraZeneca at 26.7% of the total.

$348in general payments, 2019–2025

Across 15 payments — averaging $23.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$93
  • Novartis$78
  • Johnson & Johnson$46
  • Pfizer$39
  • Abbott$32
  • Boehringer Ingelheim$30
  • plus $30 from 2 others

What the payments were for

  • Food & beverage$30287%
  • Education$4613%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$348 in reported general payments places this provider in the 65th percentile of 124 medical providers in New Hampshire.

See all medical providers in New Hampshire

Medicare billing

Part B allowed, 2024
$48,001
Medicare patients
267
Services billed
450

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban118$134,620
EntrestoSacubitril/Valsartan43$55,724
FarxigaDapagliflozin Propanediol52$52,395
XareltoRivaroxaban21$29,789
Metoprolol Succinate160$1,821
Rosuvastatin Calcium49$1,237
Valsartan30$1,000
Atorvastatin Calcium81$694
Torsemide20$558
Ezetimibe23$504
Pravastatin Sodium12$426
SotalolSotalol Hcl15$402
ClopidogrelClopidogrel Bisulfate24$399
Carvedilol35$330
Amiodarone Hcl27$320

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$39$134,620118 claims
NovartisEntresto$78$55,72443 claims
AstraZenecaFarxiga$93$52,39552 claims
Johnson & JohnsonXarelto$46$29,78921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 124 medical providers in New Hampshire.

Other medical in Nashua

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →